Articoli Scientifici su Riviste Impattate “Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?” di Redazione Dicembre 5, 2020 scritto da Redazione Dicembre 5, 2020 71 Articolo 0 commento Redazione messaggio precedente “Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction” prossimo post “A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology” Potrebbe piacerti anche “Women survive breast cancer but fall victim to heart failure: the shadows and lights of... Dicembre 5, 2020 “Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience” Dicembre 5, 2020 “Intracardiac metastasis originated from chondrosarcoma” Dicembre 5, 2020 “Complete atrioventricular block in a patient with intracardiac metastases from malignant melanoma” Dicembre 5, 2020 “Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors” Dicembre 5, 2020 “Early identification of left ventricular dysfunction induced by trastuzumab” Dicembre 5, 2020 “Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge” Dicembre 5, 2020 “Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer” Dicembre 5, 2020 “Administration of angiotensin-coverting enzyme inhibitors and B-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer:... Dicembre 5, 2020 “Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: a... Dicembre 5, 2020
